Introduction
Multi-drug-resistant tuberculosis (MDR-TB), defi ned as the resistance to at-least rifampicin (RIF) and isoniazid (INH), poses grave challenge because of prolonged, limited and expensive treatment options with 10-30% of cases resulting in failure of treatment and death. [1] Timely diagnosis and treatment of infectious cases is crucial in curtailing the spread of infection in the community. Hence, it is imperative to perform drug susceptibility testing (DST) for appropriate management of drug-resistant cases.
Conventional DST such as 1% proportion method has been the gold standard but takes up to 4-6 weeks after the resistance could differ as per region and thus provide an insight into the epidemiology of the disease. Therefore, the present study was co nducted to determine the MDR and mutations in rpoB, katG and inhA gene using GenoType MTBDRplus assay.
Materials and Methods

Study setting
A total of 2891 sputum samples from MDR-TB suspect patients were received from fi ve districts of Delhi under RNTCP from 1 st October 2011 to 31 st December 2012. The TB patients were suspected as MDR-TB as per criterion A, B and C implemented in New Delhi [ Table 1 ]. [6] The study is approved by institute's ethical committee.
Sample processing
All specimens were screened for presence of acid fast bacilli (AFB) by Ziehl-Neelsen (ZN) staining. [7] The samples were processed by N-acetyl-L cysteine-Sodium hydroxide (NALC-NaOH) method of digestion and decontamination. [8] The pellet obtained was suspended in 2 ml of phosphate buffer saline (PBS) at pH 6.8. All smear-positive processed sputum samples (≥1 + for version 1.0) were directly processed for GenoType MTBDRplus assay as per the national guidelines. [6] Culture All smear-negative processed samples and scanty positive samples (version 1.0) were inoculated in MGIT 960 tubes for culture as per national guidelines. [6] Tubes with positive alerts were identifi ed for presence of M. tuberculosis by smear microscopy for serpentine cording and rapid immunochromatographic test for detection of MPT64 TB Ag (SD BIOLINE). Cultures positive for M. tuberculosis were subjected to LPA.
GenoType MTBDRplus assay
The Genotype MTBDRplus assay version 1.0 or version 2.0 (Hain Life Sciences, Nehran, Germany) was carried out on the processed sample as per manufacturer's instructions. [3] DNA extraction, master-mix preparation, DNA amplifi cation and hybridization were done after thorough cleaning in dedicated rooms. [3] For DNA extraction, 500 l of NaLC-NaOH processed samples and 1 ml of M. tuberculosis cultures from MGIT tubes were taken. The processed samples or cultures were pelleted in 100 l sterile molecular grade water. In version 1.0, bacterial pellets were heat inactivated at 95°C for 20 minutes and sonicated; in version 2.0, bacterial pellets were subjected to chemical lysis using the Genolyse kit. The supernatant containing DNA was transferred into the fresh tube and stored at -20°C.
Master-mix was prepared using reagents provided in the kit and addition of TAQ polymerase as supplied in the two versions of the kit. DNA solution was added in volumes of 5 l to PCR tubes and amplifi ed. Detection of PCR products was done using hybridization by LPA methodology by GenoType MTBDRplus. [3] Reporting The result of DNA strips was interpreted with the help of reporting card as resistant or sensitive for RIF or INH or invalid based on the kit insert. In addition, presence of mutation bands and absence of sensitive bands were also recorded. [3] Testing of LPA on any invalid results were repeated using processed sample deposits, stored at −20°C. M. tuberculosis H37Rv (ATCC 27294) was run as positive control and sterile molecular grade water was run as negative control, in each run for quality control.
The reports were communicated electronically to the District TB Offi cers (DTO) of the respective districts within 24 hours of report generation. Turn-around time for each sample was calculated.
Statistical analysis
Data were presented as frequency tables, and mean was calculated wherever required. Fisher's exact test for statistical signifi cance (defi ned as the probability that an effect is not due to by chance alone) was calculated wherever applicable using Graphpad computer software. P < 0.05 was considered signifi cant. 
Results
Study population
Out of 2891 samples from MDR suspects received, 2043 were males and 848 were females (ratio of 2.4:0). Maximum patients were found in the age groups of 16-35 (1507; 52.1%). A total of 181 and 161 patients were found to be aged more than 60 years and less than or equal to 15 years, respectively. Smear-positive and smear-negative patients were found to be 2120/2891 (73.3%) and 771/2891 (26.7%), respectively. The district-wise distribution of patients is detailed in Table 2 .
MDR results
A total of 2182 GenoType MTBDRplus tests were conducted. Of these, 1961 were done directly on samples and 221 on positive cultures. Valid LPA results were obtained for 2038 out of 2182 samples (93.4%) on which LPA was performed. Of 2038, 366 (17.9%) tests were found to be resistant to RIF and INH, 93/2038 (4.6%) as mono-RIF-resistant, 148/2038 (7.3%) as mono-INH-resistant and 1431/2038 (70.2%) as sensitive to both RIF and INH [ Table 3 ]. The MDR-TB rate detected among MDR suspects was found to be 39/122 (32%), 108/652 (16.6%) and 219/2117 (10.2%) during criteria A, B and C, respectively. This difference of MDR-TB rate diagnosed in criteria A, B and C was signifi cant (P < 0.0001).
Correlation of valid GenoType MTBDRplus with smear microscopy result
Overall, 144/2038 (6.6%) of tests were found to be invalid. The invalid rate increased as 4/572 (0.7%), 10/371 (2.7%), 123/907 (13.6%) and 7/40 (17.5%) as AFB concentration decreased as 3+, 2+, 1+ and scanty. This correlation was statistically highly signifi cant. (P < 0.0001).
Turn-around time (TAT)
An average TAT of 5.5 days, 4.2 days, 5.3 days, 4.3 days and 3.3 days was achieved in IV th Q 2011, I st Q 2012, II nd Q 2012, III rd Q 2012 and IV th quarter 2012, respectively, for LPA performed directly on samples with overall average of 4.4 days. TAT for phenotypic DST by liquid culture was 27.2 days.
Mutation pattern of RIF
Among 459 RIF-resistant strains, missing wild type with known mutations were found in 339 (73.9%) strains [ Table 4 ]. Commonest specifi c mutation was S531L in rpoB (267/459, 58.2%) followed by D516V (37/459, 8%), H526Y (23/459, 5%) and H526D (6/459, 1.3%). In six strains, more than one mutation was found. The mutation S531L was found in 231/366 (63.1%) and 36/93 (38.7%) of MDR strains and mono-RIF strains, respectively. This difference was highly statistically signifi cant (P < 0.0001). In 120/459 (26.1%) of RIF-resistant strains, one or more wild type probes were missing with no presence of mutant probes. Such mutations were found more commonly in mono-RIF strains than MDR strains (P < 0.0001). These included missing wild type bands WT8 (53/120, 44.2%), WT7 (14/120, 11.7%), WT3 (4/120, 3.3%), WT2 (10/120, 8.3%), WT1 (4/120, 3.3%), WT6-WT7 (1/120, 0.8%), WT5-WT6 (2/120, 1.7%), WT3-W8 (1/120, 0.8%), W3-W4 (20/120, 16.7%), W2-W3 (5/120, 4.2%), WT6-WT7-WT8 (1/120, 0.8%), WT4-WT5-W8 (1/120, 0.8%), WT3-W4-W7 (1/120, 0.8%) and WT2-WT3-WT4 (3/120, 2.5%) [ Table 4 ]. Mixed pattern to RIF with all wild type probes present along with one A  86  81  5  80  39  6  7  28  I 2012  B  543  488  55  501  108  17  35  341  II 2012  C  658  563  95  590  103  24  43  420  III 2012  C  472  446  26  445  62  29  27  327  IV 2012  C  423  383  40  422  54  17  36  315  Total  2182  1961  221  2038  366  93  148  1431 MDR: Multi-drug-resistant, CR: Criteria, RIF: Rifampicin, INH: Isoniazid, SENS: Sensitive, RES: Resistance S49 February or more mutant bands was found in (22/459; 4.8%) cases, most common being S531L (8/459; 1.7%) and D516V mutation (7/459; 1.5%).
Mutation pattern of INH
Among 514 INH-resistant strains detected, katG mutation occurred in 479 (93.2%). Known mutation S315T1 was found in 454/514 (88.3%) of INH-resistant strains or 454/479 (94.8%) of katG mutant strains. Missing wild type with absence of mutant probes among katG was found in 19/479 (4.0%) strains. Mutations in S315T1 and katG were signifi cantly higher in MDR strains than INH mono-resistant strains (P value < 0.0001). InhA mutations were found in 69/514 (13.4%) of INH-resistant strains which included C15T (53/69, 76.8%), T8C (4/69, 5.8%), T8A (2/69, 2.9%), A16G (1/69, 1.5%) and (9/69, 13.0%) due to missing wild type with no mutation band. Mutations in C15T and inhA were signifi cantly higher in INH mono-resistant than MDR strains (P < 0.0001). Both inhA and katG mutations were seen in 34/514 (6.6%) of isolates [ Table 5 ]. Mixed wild-type and mutant pattern to INH was found in 26/514 (5.1%) cases.
Discussion
A study of MDR-TB detection among MDR-TB suspects in North Indian RNTCP network using the GenoType MTBDRplus assay was conducted. The genotypic profi les of the rpoB, katG and inhA regions associated with resistance were also reviewed.
Males were found to be predominant in the present study with 70.7%. Maximum patients were found in young age group of 16-35 years, 1507 (52.1%) as seen earlier. [9] As young adult males are economically productive segment of society, high MDR-TB in this group has several socioeconomic implications.
Overall, MDR rate among MDR suspects tested was 17.9%. There was a signifi cant reduction in MDR-TB rate from criteria A to B and then C. This could be because under PMDT, MDR-TB are suspected among the notifi ed TB cases initially from highly selective group of patients with high probability of MDR-TB to gradually expand and provide universal access of MDR-TB diagnostics for most TB patients. [6] Various Indian studies have reported MDR rates to be varying from 17.4% to 53% among re-treatment cases. [10, 11] World-wide surveillance of MDR in re-treatment cases ranged from 9.4% to 36.5%, from 1994-2000 across the world. [12] Previous exposure to anti-tuberculosis agents is the most common cause of developing MDR.
GenoType MTBDRplus assay directly performed on samples gave an average TAT of 4.4 days, a signifi cant reduction by 83.8% compared to phenotypic DST by liquid culture (27.2; unpublished information). This is one of the main advantages of the assay as reported earlier. [2] One lot of DNA extraction to hybridization procedure is completed in less than two working days; however, initial AFB screening, report typing and dispatch adds to TAT. The management of MDR-TB in our hospital has been accelerated as almost 95% of patients diagnosed as MDR-TB are started on category IV treatment within 1 week of communication of report.
The invalid results obtained for some samples are well within the acceptable limits. [3] The rate of invalid obtained correlated inversely to AFB microscopy grading as has also been reported earlier. [13] Therefore, the test may have limited use in pauci-bacillary extra-pulmonary cases.
The GenoType MTBDRplus provides comprehensive information about the mutations leading to resistance, which highly correlates with the sequencing results. [14] In the present study, the test identifi ed RIF resistance by one of the four rpoB mutant probes in 73.9% isolates, much lesser than in a South African study (91%). [13] Mutation S531L was detected in 59.0% of RIF resistance cases, similar to other Indian studies; 59.8% and 84.6% cases. [15, 16] Internationally, S531L mutation has been detected in rates varying from 47% to 70.5%. [3, 13, 17] In the present study, S531L mutation occurred signifi cantly more in MDR strains in comparison to RIF mono-resistant strains (P value < 0.0001). This has been seen in a South African study and an Indian study. [13, 18] In South African and Indian studies, S531L mutation accounted for 76.4% and 37.5% and 55% and 19% of MDR-TB and RIF mono-resistant strains, respectively, which is a signifi cant difference. [13, 18] The missing wild type probe without any mutant bands was found in 26.1% of RIF-resistant isolates as also reported in other studies in France (29%), New Delhi (11.1%) and Vietnam (33.3%). [3, 16, 17] As the GenoType MTBDRplus incorporates the probes for common mutations only, these isolates could have uncommon mutations. Interestingly, such mutations were found signifi cantly more in mono-RIF-resistant strains. One limitation of the study is the lack of sequencing which could have identifi ed such mutations.
The katG gene mutations account for commonest mechanism of resistance for INH. Specifi c mutation S315T1 in katG was found in 88.3% of INH-resistant isolates, similar to other studies. [19, 20] However, variations have been reported in studies from France (62.5%) and South Africa (37.6%). [3, 13] High prevalence of katG mutations contributes to most cases of INH resistance in high-burden countries and leads to high-level INH resistance. A signifi cant difference in prevalence of S315T1 in MDR strains as compared to mono-INH-resistant strains was found (P < 0.0001) as also reported in South African and Indian studies. [13] Mutation in the inhA gene accounts for low-level resistance. It was found to be 13.4%, similar to studies elsewhere 5.4-21.1%. [3, [15] [16] [17] [18] [19] The inhA mutations accounted for 30% and 9% of mono-INH and MDR strains, respectively. This difference was found to be highly signifi cant. In the South African and Indian studies, [13, 18] The South African study reported high prevalence of inhA mutations among all INH-resistant cases (41.7%). [13] The current assay offers additional detection of INH-resistant strains due to mutations in inhA gene, which was lacking in the earlier version (Genotype MTBDR assay).
Hetero-resistance, i.e. presence of all wild type probes along with presence of one or more mutant bands was found in 4.8% of RIF-resistant strains and 5.1% of INH-resistant strains. Tolani et al. from Mumbai have reported high number of hetero-resistant strains. [21] The detection of hetero-resistant strains would ensure the timely initiation of MDR-TB regimens in such patients. Patients harbouring such strains would have better treatment outcomes compared to pure MDR-TB patients. [21] A disadvantage of this genotypic test is a possibility of silent mutation, i.e. mutations that do not lead to amino acid change with, the strain being sensitive by phenotypic DST. In an earlier study from NRL, the test was compared with phenotypic DST. [16] To conclude, LPA with GenoType MTBDRplus has revolutionized the MDR-TB diagnosis. Less staff is able to complete far more number of DSTs per day. In addition, TAT is substantially reduced promoting early detection and management of drug-resistant cases. The test provides additional information of the common mutations imparting resistance to RIF and INH, which helps in understanding the epidemiology of the disease. More studies need to be instituted to assess the performance of the test in smear negative patients at larger platforms.
